For years, the European life science map has been dominated by a familiar set of established markets. However, the Investment and Development Agency of Latvia (LIAA) is challenging that status quo, positioning the country as an agile alternative for R&D, manufacturing, and clinical operations. The upcoming session, featuring LIAA’s Deniss Čamovs and Annija Veinsteina, will detail the practical realities of entering the Latvian market, from navigating regulatory frameworks to accessing a specialized, multilingual talent pool.

Latvia’s appeal rests on a combination of strategic geography and a maturing innovation ecosystem. By integrating world-class research institutions with dedicated Special Economic Zones, the country has begun to mirror the capabilities of larger neighbors while maintaining a more responsive business environment. LIAA representatives will outline how they serve as a long-term partner, guiding organizations from initial site selection through to sustained operational growth. For executives evaluating their next European base, the discussion provides a direct look at the incentives and infrastructure currently driving investment into the Baltic region.